Skip to main content

Table 2 Patient characteristics and medical history

From: Development and content validation of the Satisfaction and Experience Questionnaire for Granulocyte Colony-Stimulating Factor (SEQ-G-CSF)

Characteristics Breast Cancer
N = 10
Lung Cancer
N = 10
Non-Hodgkin Lymphoma
N = 10
Prostate Cancera
N = 10
Total
N = 40
Gender, n (%)
 Male 0 (0) 6 (60) 4 (40) 10 (100) 20 (50)
 Female 10 (100) 4 (40) 6 (60) 0 (0) 20 (50)
Age
 Mean (SD) years 47.0 (9.3) 52.3 (17.1) 52.8 (14.0) 52.6 (5.7) 51.1 (12.4)
 Median (range) years 51 (30–55) 51 (34–90) 52 (30–76) 51 (47–64) 52 (30–90)
Ethnicity, n (%)
 Not Hispanic or Latino 9 (90) 10 (100) 10 (100) 7 (70) 36 (95)
 Missing 1 (10) 0 (0) 0 (0) 3 (30) 4 (10)
Racial background, n (%)
 Asian 0 (0) 2 (20) 0 (0) 1 (10) 3 (8)
 Black or African American 4 (40) 0 (0) 0 (0) 0 (0) 4 (10)
 White 6 (60) 8 (80) 10 (100) 5 (50) 29 (73)
 Missing 0 (0) 0 (0) 0 (0) 4 (40) 4 (10)
Employment status, n (%)b
 Employed, full-time 5 (50) 5 (50) 5 (50) 6 (60) 21 (53)
 Employed, part-time 3 (30) 2 (20) 3 (30) 0 (0) 8 (20)
 Homemaker 1 (10) 0 (0) 1 (10) 0 (0) 2 (5)
 Unemployed 0 (0) 1 (10) 0 (0) 0 (0) 1 (3)
 Retired 0 (0) 0 (0) 1 (10) 0 (0) 1 (3)
 Disabled 1 (10) 2 (20) 0 (0) 0 (0) 3 (8)
 Missing 0 (0) 0 (0) 0 (0) 4 (40) 4 (10)
Highest level of education, n (%)b
 Secondary/high school 0 (0) 1 (10) 1 (10) 0 (0) 2 (5)
 Some college 2 (20) 0 (0) 1 (10) 1 (10) 4 (10)
 College degree 7 (70) 4 (40) 5 (50) 4 (40) 20 (50)
 Postgraduate degree 1 (10) 5 (50) 3 (30) 1 (10) 10 (25)
 Bachelor of Science/Bachelor of Arts 0 (0) 0 (0) 1 (10) 0 (0) 1 (3)
 Missing 0 (0) 0 (0) 1 (10) 4 (40) 5 (13)
Insurance status, n (%)
 Insured, minimal out-of-pocket costs 6 (60) 9 (90) 8 (80) 4 (40) 27 (68)
 Insured, significant out-of-pocket costs 4 (40) 1 (10) 2 (20) 2 (20) 9 (23)
 Missing 0 (0) 0 (0) 0 (0) 4 (40) 4 (10)
Time since cancer diagnosis, n (%)
 <  6 months 3 (30) 0 (0) 2 (20) 2 (20) 7 (18)
 6 months to 1 year 4 (40) 6 (60) 1 (10) 0 (0) 11 (28)
 1–2 years 1 (10) 2 (20) 4 (40) 1 (10) 8 (20)
 2–3 years 2 (20) 1 (10) 0 (0) 3 (30) 6 (15)
 3+ years 0 (0) 1 (10) 3 (30) 2 (20) 6 (15)
 Missing 0 (0) 0 (0) 0 (0) 2 (20) 2 (5)
Metastatic cancer 2 (20) 6 (60) 4 (40) 4 (40) 16 (40)
Currently receiving chemotherapy 8 (80) 6 (60) 4 (40) 3 (30) 21 (53)
Last chemotherapy treatment
 <  6 months 10 (100) 9 (90) 7 (70) 7 (70) 33 (83)
 6 months to 1 year 0 (0) 0 (0) 3 (30) 1 (10) 4 (10)
 1–2 years 0 (0) 1 (10) 0 (0) 0 (0) 1 (3)
 Missing 0 (0) 0 (0) 0 (0) 2 (20) 2 (5)
Recently received or currently receiving G-CSF prophylaxis
 Currently receiving 7 (70) 3 (30) 1 (10) 1 (10) 13 (33)
 Recently completed 3 (30) 7 (70) 9 (90) 7 (70) 13 (33)
 Missing 0 (0) 0 (0) 0 (0) 2 (20) 2 (5)
Type of G-CSF prophylaxisb
 Pegfilgrastim 5 (50) 4 (40) 5 (50) 5 (50) 19 (48)
 Filgrastim 5 (50) 6 (60) 5 (50) 2 (20) 18 (45)
 Missing 0 (0) 0 (0) 0 (0) 2 (20) 2 (5)
Last G-CSF treatment, n (%)
 <  6 months 7 (70) 9 (90) 7 (70) 7 (70) 30 (75)
 6 months to 1 year 1 (10) 1 (10) 2 (20) 1 (10) 5 (13)
 1–2 years 0 (0) 0 (0) 1 (10) 0 (0) 1 (3)
 Missing 2 (20) 0 (0) 0 (0) 2 (20) 4 (10)
Route of administration of G-CSF prophylaxisb
 Subcutaneous 5 (50) 1 (10) 6 (60) 3 (30) 15 (38)
 Intravenous 2 (20) 5 (50) 2 (20) 2 (20) 11 (28)
 OBI 3 (30) 4 (40) 2 (20) 3 (30) 12 (30)
 Missing 0 (0) 0 (0) 0 (0) 2 (20) 2 (5)
Have you ever used an OBI for G-CSF treatment?
 Yes 4 (40) 7 (70) 4 (40) 7 (70) 22 (55)
Comorbidities
 No other health condition 10 (100) 10 (100) 9 (90) 8 (80) 37 (93)
 Cardiovascular disease 0 (0) 0 (0) 1 (10) 0 (0) 1 (3)
 Missing 0 (0) 0 (0) 0 (0) 2 (20) 2 (5)
Health status within the past week
 Excellent 2 (20) 0 (0) 3 (30) 1 (10) 6 (15)
 Very good 0 (0) 1 (10) 3 (30) 2 (20) 6 (15)
 Good 4 (40) 5 (50) 3 (30) 3 (30) 15 (38)
 Fair 4 (40) 4 (40) 1 (10) 2 (20) 11 (28)
 Missing 0 (0) 0 (0) 0 (0) 2 (20) 2 (5)
  1. Abbreviations: G-CSF granulocyte colony-stimulating factor, NHL non-Hodgkin lymphoma, OBI on-body injector, SD standard deviation
  2. aTwo of the ten participants with prostate cancer did not return their study forms
  3. bData are not mutually exclusive